Last reviewed · How we verify
HuL001
At a glance
| Generic name | HuL001 |
|---|---|
| Also known as | Anti-Enolase 1 monoclonal antibody |
| Sponsor | HuniLife Biotechnology, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients (PHASE1, PHASE2)
- A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HuL001 CI brief — competitive landscape report
- HuL001 updates RSS · CI watch RSS
- HuniLife Biotechnology, Inc. portfolio CI